July 20, 2020

Anti-cancer start-up doses first patient in new clinical trial

Vyriad, a growing Rochester biotech firm founded by Mayo Clinic researcher Dr. Kah-Whye Peng and Dr. Stephen Russell, has started dosing of the first patient in a Phase 2 clinical trial of a possible late-stage cancer treatment.

Media Inquiries

For inquiries, please contact mediarelations@vyriad.com